The modified version of Nitisinone Tablet (Test Product 2, higher glyceryl dibehenate (Compritol 888)) was administered to determine the acceptance limit of the dissolution profile for Nitisinone tablets with a longer dissolution time (Test Product 2) since the dissolution time of Nitisinone tablets (Test Product 1) lengthened over time under accelerated study conditions. The hypothesis is that should bioequivalence between Test Product 1 and Test Product 2 be demonstrated then it is concluded that the prolonged dissolution time had no impact on the bioequivalence of Nitisinone tablets.